12.93
-0.19 (-1.45%)
| Penutupan Terdahulu | 13.12 |
| Buka | 13.14 |
| Jumlah Dagangan | 530,424 |
| Purata Dagangan (3B) | 1,936,322 |
| Modal Pasaran | 738,107,008 |
| Harga / Jualan (P/S) | 1.04 |
| Harga / Buku (P/B) | 5.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -1.88 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.75% |
| Nisbah Semasa (MRQ) | 17.39 |
| Aliran Tunai Operasi (OCF TTM) | -96.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.11 M |
| Pulangan Atas Aset (ROA TTM) | -22.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -32.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Astria Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.25 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.49% |
| % Dimiliki oleh Institusi | 106.43% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 49.00 (Cantor Fitzgerald, 278.96%) | Beli |
| Median | 16.50 (27.61%) | |
| Rendah | 13.00 (Wedbush, 0.54%) | Pegang |
| 13.00 (Jefferies, 0.54%) | Pegang | |
| Purata | 23.75 (83.68%) | |
| Jumlah | 2 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 9.58 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 15 Oct 2025 | 13.00 (0.54%) | Pegang | 11.92 |
| Jefferies | 14 Oct 2025 | 13.00 (0.54%) | Pegang | 11.61 |
| Cantor Fitzgerald | 17 Sep 2025 | 49.00 (278.96%) | Beli | 7.39 |
| HC Wainwright & Co. | 17 Sep 2025 | 20.00 (54.68%) | Beli | 7.39 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |